Our discovery of significant interactions between SLC39A1 and genes related to citrate metabolism, notably SLC25A1, suggests potential new therapeutic targets for further investigation in the context of prostate cancer and other SLC39A1-related disorders. Here, SLC25A1 is linked to prostate carcinoma.